Connection

Mark Kindy to Amyloid beta-Peptides

This is a "connection" page, showing publications Mark Kindy has written about Amyloid beta-Peptides.
Connection Strength

3.519
  1. GM6 Attenuates Alzheimer's Disease Pathology in APP Mice. Mol Neurobiol. 2019 Sep; 56(9):6386-6396.
    View in: PubMed
    Score: 0.555
  2. Transcranial laser therapy attenuates amyloid-? peptide neuropathology in amyloid-? protein precursor transgenic mice. J Alzheimers Dis. 2011; 23(3):521-35.
    View in: PubMed
    Score: 0.315
  3. The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
    View in: PubMed
    Score: 0.315
  4. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
    View in: PubMed
    Score: 0.306
  5. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol. 2008 May; 172(5):1342-54.
    View in: PubMed
    Score: 0.261
  6. Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem. 2007 Sep; 388(9):979-83.
    View in: PubMed
    Score: 0.250
  7. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res. 2007 Jun 04; 1152:191-200.
    View in: PubMed
    Score: 0.243
  8. cAMP-induced decrease in cell-surface laminin receptor and cellular prion protein attenuates amyloid-? uptake and amyloid-?-induced neuronal cell death. FEBS Lett. 2022 11; 596(22):2914-2927.
    View in: PubMed
    Score: 0.176
  9. Effects of GrandFusion Diet on Cognitive Impairment in Transgenic Mouse Model of Alzheimer's Disease. Nutrients. 2020 Dec 30; 13(1).
    View in: PubMed
    Score: 0.158
  10. Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
    View in: PubMed
    Score: 0.097
  11. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
    View in: PubMed
    Score: 0.085
  12. Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim Biophys Acta. 2012 Jan; 1824(1):89-104.
    View in: PubMed
    Score: 0.083
  13. A new target for amyloid beta toxicity validated by standard and high-throughput electrophysiology. PLoS One. 2010 Jan 08; 5(1):e8643.
    View in: PubMed
    Score: 0.074
  14. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun. 2009 Aug 21; 386(2):284-8.
    View in: PubMed
    Score: 0.071
  15. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem. 2007 Feb; 388(2):247-52.
    View in: PubMed
    Score: 0.060
  16. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005 Feb 01; 14(3):447-60.
    View in: PubMed
    Score: 0.052
  17. Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci. 2004; 22(1-2):5-11.
    View in: PubMed
    Score: 0.049
  18. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003 Jul; 9(7):907-13.
    View in: PubMed
    Score: 0.047
  19. Abeta deposition is essential to AD neuropathology. J Alzheimers Dis. 2002 Jun; 4(3):133-8.
    View in: PubMed
    Score: 0.043
  20. Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 2002 Jan 04; 924(1):90-7.
    View in: PubMed
    Score: 0.042
  21. Key signaling pathways regulate the biological activities and accumulation of amyloid-beta. Neurobiol Aging. 2001 Nov-Dec; 22(6):967-73.
    View in: PubMed
    Score: 0.042
  22. Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer's disease. Biochemistry. 2001 Feb 27; 40(8):2548-54.
    View in: PubMed
    Score: 0.040
  23. Control of ?-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-?/? and Nuclear Factor ?-B. Curr Alzheimer Res. 2021; 18(12):941-955.
    View in: PubMed
    Score: 0.039
  24. Amyloid beta-peptide effects on synaptosomes from apolipoprotein E-deficient mice. J Neurochem. 2000 Apr; 74(4):1579-86.
    View in: PubMed
    Score: 0.037
  25. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996 Sep 24; 226(3):672-80.
    View in: PubMed
    Score: 0.029
  26. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 2008 Jul; 106(1):475-85.
    View in: PubMed
    Score: 0.017
  27. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003 Mar 15; 23(6):1992-6.
    View in: PubMed
    Score: 0.011
  28. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis. 2002 Jun; 4(3):145-54.
    View in: PubMed
    Score: 0.011
  29. Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress. Free Radic Biol Med. 2001 Jul 01; 31(1):73-81.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.